ArticleJournal of nanobiotechnology2026
3D-printed implantable CAR-macrophages for post-surgery cancer immunotherapy.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A narrative review of barrier-matched engineering of macrophages for solid tumor immunotherapy: design logic, translational barriers and clinical outlook.Translational cancer research · 2026Review
- Chimeric antigen receptor-macrophages: A new paradigm for cell therapy.Bioengineering & translational medicine · 2026Review
- Applications of synthetic biology in biomedicine.Molecular biomedicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Chimeric antigen receptor macrophages (CAR-M) therapy holds significant clinical potential, while its application is severely compromised by poor in vivo colonization and limited persistence. Here, we report a 3D-printed implantable CAR-M (iCAR-M) system, composed of a gelatin methacrylate (GelMA) scaffold loaded with IL13Rα2-targeting CAR-M, and signal regulatory protein-α-overexpressing extracellular vesicles (SIRPα-EVs). Functioning as a bioactive reservoir, the porous hydrogel mitigates anoikis and promotes nutrient transport, markedly elevating CAR-M viability and increasing the frequency of activated macrophages in mice from ~ 5% to ~ 30% after 7 days. Mechanistically, the co-released SIRPα-EVs mask CD47 on tumor cells to abrogate the "don't eat me" signal, synergizing with CAR-mediated phagocytosis. In a 4T1 post-surgery model, this locoregional delivery system significantly inhibited tumor recurrence and remodeled the immunosuppressive microenvironment, boosting CD80⁺ macrophage polarization ~ 24% and CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.